MedTrace Logo

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

NCT07239973 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-11-20

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.

Conditions

  • Healthy
  • Non-diabetic Overweight or Obese

Interventions

DRUG

BGM0504 tablets

Administered p.o.

DRUG

Placebo tablets

Administered p.o.

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-21
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07239973 on ClinicalTrials.gov